News

CRISPR Therapeutics stock has delivered a decline of about 61% over the past five years, yet current valuation checks suggest the shares now sit closer to "about right" territory rather than looking clearly cheap or clearly expensive. The roughly 60.9% five year share price decline points to investors reassessing how much they are willing to pay for CRISPR Therapeutics' long term gene editing opportunity. Strong cash of around US$2.4b that has been highlighted in recent coverage can support...

In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, and Small Cap Comp Growth benchmarks. This broad index inclusion increases the company’s visibility to benchmarked funds and could meaningfully influence how investors view its role in growth-oriented portfolios. We’ll now examine how this broad Russell growth index inclusion shapes CRISPR Therapeutics’ investment narrative and...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.